



HALF-YEAR REPORT FOR THE FIRST HALF OF 2021

Second quarter 2021


- **Net sales** rose by 26% to SEK 19,535 (15,490) thousand. Growth is 37%, adjusted for currency effects.
- **Gross profit** rose by 32% to SEK 17,365 (13,146) thousand.
- **Operating profit before depreciation and amortization (EBITDA)** totaled SEK 2,793 (loss: 38) thousand.
- **Operating profit** improved by SEK 2,641 thousand and totaled SEK 1,350 (loss: 1,291) thousand.
- **Comprehensive income for the period** improved by SEK 4,156 thousand and totaled SEK 1,033 (loss: 3,123) thousand.
- **Comprehensive income per share**, basic and diluted, totaled SEK 0.01 (-0.02).
- **Cash flow from operating activities** was SEK -1,747 (-123) thousand.
- **Cash and cash equivalents at the end of the period** totaled SEK 41,730 (46,554) thousand.

(SEK 000s)	April – June		Jan. – June		full-year 2020
	2021	2020	2021	2020	
Net sales	19,535	15,490	35,258	26,965	61,030
Gross profit	17,365	13,146	32,382	24,123	59,370
Operating profit/loss (EBIT)	1,350	-1,291	1,901	-3,180	3,140
Comprehensive income for the period	1,033	-3,123	2,640	-5,038	1,973
Cash flow from operating activities	-1,747	-123	1,765	-1,629	3,755
Cash and cash equivalents at close of period	41,730	46,554	41,730	46,554	44,118
Earnings per share* (SEK)	0.01	-0.02	0.02	-0.05	0.10

First half 2021

- **Net sales** rose by 31% to SEK 35,258 (26,965) thousand. Growth is 45%, adjusted for currency effects.
- **Gross profit** rose by 34% to SEK 32,382 (24,123) thousand.
- **Operating profit before depreciation and amortization (EBITDA)** totaled SEK 4,751 (-885) thousand.
- **Operating profit** improved by SEK 5,081 thousand and totaled SEK 1,901 (loss: 3,180) thousand.
- **Comprehensive income for the period** improved by SEK 7,678 thousand and totaled SEK 2,640 (loss: 5,038) thousand.
- **Comprehensive income per share**, basic and diluted, totaled SEK 0.02 (-0.05).
- **Cash flow from operating activities** was SEK 1,765 (-1,629) thousand.

Sales by quarter 2018 – 2021



Comments from Fredrik Olsson, Chief Executive Officer

We continue to show good growth for the second quarter of 2021. Our currency-adjusted growth totaled 37% compared with the corresponding quarter the previous year and we posted increased sales in both the enzyme and the antibody business. Currency-adjusted growth totaled 41% for the enzyme business and 4% for the antibody business.



We continue to be affected by subdued customer activity for enzymes in our Analytics segment due to Covid-19, as reflected by delayed customer projects and changed priorities in research where our products are used. The pandemic has also impacted access to other products that are included in our customers' analysis flow, which has affected their productivity. We were also subjected to disruptions in global logistics chains during the quarter, while restrictions and delays in customer projects had a dampening effect on the antibody business.

Despite these challenges, we delivered strong growth, driven by both organic growth among existing customers and new applications for our products, thereby demonstrating the power of our innovative customer-focused business model and organization.

Antibody labeling is an exciting field in which we have expanded our customer offering over time. We have now taken yet another step in the field through our license agreement with GlycoT Therapeutics. At the end of the second quarter we launched the first products based on a combination of our enzyme technologies, which offer a completely new approach to designing antibodies with a defined glycan structure. The technology platform opens up several potential new markets and areas of application for us, including research, diagnostics and antibody drug conjugates (ADCs), and we intend to broaden our offering further in the future.

We continue to follow our product development strategy through the additional launches of two new products. In the most recent quarter, in addition to TransGLYCIT as described above, we launched antibody products developed in our subsidiary as a complement to our enzyme business. Several projects are underway in the antibodies business where we are leveraging synergies from our acquisition last year. Our ability to develop new enzymes over time is further strengthened by the initiation of our novel enzyme screening project at the end of the quarter, for which we have received financial support from Vinnova. With continued good momentum in our product development activities, I look forward to more product launches in the second half of the year.

As part of our previously announced collaboration with Waters, we initiated and conducted several joint projects to develop and market new automated protein analysis workflows for our customers. Some of the new methods have already been presented at virtual conferences together with Waters and our joint activities will continue during the second half of the year. Industrial partnerships will continue to be a priority to strengthen our offering of simplified and automated analysis.

Although we are still experiencing delays and subdued customer activity due to the pandemic, we continue to deliver growth, which is highly satisfying. While the Covid-19 pandemic will likely continue to impact market conditions in the second half of the year, I am optimistic about Genovis' growth potential over time.

Finally, I would like to thank all my colleagues at Genovis who are doing a fantastic job by helping our customers on a daily basis to access innovative products to develop the medicines of the future, which will result in continued growth.

Genovis Group in brief

Genovis will apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future.



The Group's enzymes and antibodies are in a market that covers the entire life science and biotech supply industries. The Company markets a total of 15 enzymes in different product formats under the common SmartEnzymes™ brand. Until 2020, the subsidiary Genovis Inc. only served as distributor for Genovis AB's products with responsibility for the North American market. In April 2020, Genovis AB acquired all shares in QED Biosciences Inc., which immediately

merged with Genovis Inc. In addition to marketing and sales of SmartEnzymes™, Genovis Inc.'s business now also includes sales and production of antibodies for the research and diagnostics market.

The Parent Company in Lund handles sales and marketing in the European market, including development, application and support, as well as production of SmartEnzymes™. In Asia, Genovis works with direct sales, as well as with distributors who are familiar with the local market.

Central functions are governed from Genovis AB, which has a business model with a long-term and sustainable focus based on two primary strategies that together are the drivers of the Company's success:

- Continue to launch unique new products, thereby expanding the customer offering for continued good growth.
- Deliberately work to encourage customers to use Genovis products all the way to the release and approval of new biological drugs.

The Group will have a creative focus and develop unique new products that have a high value for the customer. New products are mainly aimed at customers who work in the discovery phase, preclinical development, or diagnostics. In this phase most of the Group's customers are both curious and willing to test new concepts and analytical methods to address the clear needs and challenges related to understanding, identifying and analyzing biopharmaceuticals. More and more of Genovis' customers in the biopharma industry are now using the products farther along in the value chain for biological drug development and have growing confidence in Genovis as a provider of high-quality, innovative products for the biopharma industry. A key component of Genovis' growth strategy is to continue to launch innovative products as the brand grows stronger and in pace with the expansion and broadening of our customer base.


Financial overview

Net sales

Consolidated net sales for the second quarter totaled SEK 19,535 (15,490) thousand, an increase in sales of 26%. Adjusted for currency effects, net sales totaled SEK 21,159 thousand, an increase in sales of about 37%.

Consolidated net sales for the six-month period totaled SEK 35,258 (26,965) thousand, an increase in sales of about SEK 8.2 million, or 31%. Adjusted for currency effects, net sales for the full year totaled SEK 39,188 thousand, an increase in sales of about 45%.

Sales revenue, 12-month rolling (2018 – 2021)




Operating profit before depreciation and amortization (EBITDA)

Operating profit before depreciation and amortization for the second quarter was SEK 2,793 (loss: 38) thousand, which corresponds to an increase of SEK 2,831 thousand, while operating profit before depreciation and amortization for the six-month period was SEK 4,751 (loss: 885) thousand, corresponding to an increase of SEK 5,636 thousand.

Operating profit/loss (EBIT)

Operating profit after depreciation and amortization for the second quarter was SEK 1,350 (loss: 1,291) thousand, which corresponds to an increase of SEK 2,641 thousand, while operating profit after depreciation and amortization for the six-month period was SEK 1,901 (loss: 3,180) thousand, corresponding to an increase of SEK 5,081 thousand.

Operating profit/loss (EBIT) rolling 12 months



Comprehensive income

Comprehensive income for the second quarter was SEK 1,033 (loss: -3,123) thousand, which corresponds to an increase of SEK 4,156 thousand. Earnings per share, based on a weighted average of the number of outstanding shares, totaled SEK 0.01 (-0.02).

Comprehensive income for the six-month period was SEK 2,640 (loss: 5,038) thousand, an improvement of SEK 7,678 thousand. Earnings per share, based on a weighted average of the number of outstanding shares, totaled SEK 0.02 (-0.05).

Expenses

Consolidated expenses for the second quarter totaled SEK 18,561 (16,002) thousand. Expenses are allocated as follows: raw materials and consumables SEK 2,546 (1,565) thousand, personnel costs SEK 8,310 (7,403) thousand, other external expenses SEK 5,633 (4,699) thousand and other operating expenses 629 (1,082) thousand. Depreciation and amortization for the quarter amounted to SEK 1,443 (1,253) thousand.

Expenses for the six-month period totaled SEK 34,989 (29,917) thousand. Expenses are allocated as follows: raw materials and consumables SEK 4,508 (2,614) thousand, personnel costs SEK 16,135 (13,504) thousand, other external expenses SEK 10,601 (9,068) thousand and other operating expenses 895 (2,436) thousand. Depreciation and amortization for the six-month period increased by SEK 555 to SEK 2,850 (2,295) thousand.

Investments

The Group's net capital expenditure for the second quarter totaled SEK 1,189 (15,758), including SEK 551 (487) attributable to property, plant, and equipment, primarily laboratory equipment, and SEK 638 (15,271) thousand attributable to investments in intangible assets.

Net capital expenditure for the six-month period totaled SEK 2,120 (16,499), including SEK 1,421

(882) attributable to property, plant, and equipment, primarily laboratory equipment, and SEK 699 (15,618) thousand attributable to investments in intangible assets.

Cash flow and financial position

Total shareholders' equity for the Group was SEK 89,805 (80,151) thousand after taking the result for the period into account. Equity per share based on the weighted average of the number of outstanding shares (basic and diluted) at the end of the period was SEK 1.37 (1.22). The Group's equity ratio at the end of the period was 84% (81).

Consolidated cash flow for the second quarter was SEK -4,199 (-15,087) thousand. Cash flow from financing activities totaled SEK -1,263 (794) thousand.

Consolidated cash flow for the six-month period was a loss of SEK -2,388 (31,562) thousand. Cash flow from financing activities totaled SEK -2,033 (49,690) thousand.

Consolidated cash and cash equivalents at the end of the six-month period amounted to SEK 41,730 (46,554) thousand. Taking expected revenue into account, the Board believes that the existing working capital is sufficient to run the Company over the next twelve months.

Only the Group has interest-bearing liabilities, where liabilities to credit institutions relate in their entirety to the present value of estimated future lease payments, which also includes rent for premises.

Lease liabilities (thousand)

Non-current lease liabilities

Maturity between 1 and 4 years	1,285
--------------------------------	-------

Current lease liabilities

Maturity within 1 year	3,238
------------------------	-------

Taxes

The Group has a deferred tax asset of SEK 5,972 (1,718) thousand, of which SEK 1,718 (1,718) arises from the Parent Company, and the remainder relates to deferred tax on intra-group profit on inventories of SEK 4,254 (0) thousand. It is the Board's assessment that future taxable surpluses will be available against which the unutilized tax losses can be utilized.

Employees

On June 30, 2021, the Group employed 35 people. In all, 26 people are employed by the Parent Company in Lund and nine people work for the subsidiary Genovis Inc. in the US.

Share capital and share performance

Share capital at the end of the quarter was SEK 16,366,429 and the total number of shares was 65,465,714 with a par value of SEK 0.25.

Genovis shares are traded on Nasdaq First North Growth Market under the ticker symbol GENO. First North is Nasdaq's European emerging market intended for growth companies.

Certified Adviser

Erik Penser Bank, +46 (0)8 463 83 00, certifiedadviser@penser.se.

Parent Company

Net sales and operating profit/loss in the Parent Company are attributable to the primary and only business area: sales of products and/or research-based innovations.

Revenue

Revenue for the second quarter, including change in inventory, finished goods, totaled SEK 13,523 (9,577) thousand, including SEK 12,645 (10,356) thousand attributable to sales, SEK -836 (-811) thousand relating to a change in inventory, finished goods, and SEK 1,714 (32) thousand in other revenue. Other revenue relates to foreign exchange gains and grants.

Revenue for the six-month period totaled SEK 23,209 (19,189) thousand, including SEK 21,076 (19,417) thousand attributable to sales, 224 (-811) thousand relating to change in inventory, finished goods, and SEK 1,909 (583) thousand attributable to other revenue. Other revenue relates to foreign exchange gains and grants.

Expenses

The Parent Company's expenses for the second quarter totaled SEK 11,947 (9,192) thousand. Expenses for the six-month period totaled SEK 22,257 (20,909) thousand.

Performance

Profit for the second quarter was SEK 1,576 (170) thousand, while profit for the six-month period was SEK 1,162 (loss: 1,936) thousand.

Investments

Net capital expenditure for the second quarter totaled SEK 1,189 (20,402), including SEK 551 (72) thousand attributable to property, plant, and equipment, primarily laboratory equipment, and SEK 638 (47) thousand attributable to investments in intangible assets.

Net capital expenditure for the six-month period totaled SEK 2,120 (21,144), including SEK 1,421 (467) thousand attributable to property, plant, and equipment, primarily laboratory equipment, and SEK 699 (20,495) thousand attributable to investments in intangible assets.

Taxes

The Parent Company has a deferred tax asset amounting to SEK 1,718 (1,718) thousand at the end of the period, corresponding to a loss carryforward of SEK 8,340 thousand.

It is the Board's assessment that future taxable surpluses will be available against which the unutilized tax losses can be utilized. The Company's total tax loss amounts to SEK 143 (171) million.

Subsidiary Genovis Inc.

The subsidiary Genovis Inc. handles all sales of SmartEnzymes™ in the North American market and also identifies and produces new antibodies for production of products such as biological drugs and diagnostic kits. The Company also offers customized antibody services for academia and industry.

Other information

Related party transactions

Genovis' board member and principal owner Mikael Lönn, who holds a 15.26% stake in Genovis, owns 12.24% of the shares in Redeye AB, for which Mikael Lönn is also a board member. Genovis has purchased analysis services from Redeye AB for a total of SEK 210 thousand during the period.

Events after the end of the period

No significant events were reported after the end of the period.

Outlook

Although the Life Science field is relatively independent of business cycles, periods of uncertainty can influence our customers' appetite to invest in new technology. With the majority of the development projects proceeding according to plan, Genovis is positioned to make additional advances with respect to both new products and sales. The COVID-19 outbreak during the first quarter of 2020 has had a significant impact on the current business climate. Despite the uncertainty about short-term market trends, Genovis' growth potential for the future remains intact.

Risk Factors

Genovis' general view of the financial risks that could affect operations has not changed since the description published in the most recent annual report. Genovis' business risks include the risk that anticipated revenue might not materialize since the Company is active in a market in which competing companies have substantially larger financial resources at their disposal. For a detailed overview of the Company's financial risks, please refer to page 59 in Genovis' 2020 Annual Report.

Financial calendar

Interim Report January 1 – September 30 November 11, 2021

Reports may be downloaded at the Genovis website:

<https://investor.genovis.com/sv/finansiella-rapporter/#delarsrapporter>

or requested from the company by phone or letter:

Genovis AB, Box 790

SE-220 07 Lund, Sweden T: +46 (0)46-10 12 30

Forward-looking information

This report contains forward-looking information based on the current expectations of Group management at Genovis. Although the management believes that the expectations reflected in such forward-looking information are reasonable, no assurance can be given that such expectations will prove correct. Consequently, actual future results may vary materially from those implied in the forward-looking statements due to such changes in economic, market and competitive conditions, changes in the regulatory environment and other government actions, fluctuations in exchange rates and other factors.

Accounting policies

This interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the relevant provisions of the Swedish Annual Accounts Act. The report for the Parent Company has been prepared in accordance with chapter 9 of the Swedish Annual Accounts Act, Interim Reports. The accounting policies applied for the Group and the Parent Company are consistent with the accounting policies used in the preparation of the most recent annual report.

Financial information - Group

Statement of comprehensive income

(SEK 000s)	April-June		Jan.-June		Full-year
	2021	2020	2021	2020	2020
Net sales	19,535	15,490	35,258	26,965	61,030
Change in inventory, finished goods	-1,338	-811	-277	-807	2,844
Other operating income/expenses*	1,714	32	1,909	579	1,772
Raw material and consumables	-2,546	-1,565	-4,508	-2,614	-6,276
Gross profit	17,365	13,146	32,382	24,123	59,370
Personnel costs	-8,310	-7,403	-16,135	-13,504	-28,653
Other external costs	-5,633	-4,699	-10,601	-9,068	-18,657
Other operating costs	-629	-1,082	-895	-2,436	-3,487
Operating profit before depreciation and amortization (EBITDA)	2,793	-38	4,751	-885	8,573
Depreciation, amortization, and impairment of plant, property, and equipment and intangible assets	-1,443	-1,253	-2,850	-2,295	-5,433
Operating profit/loss (EBIT)	1,350	-1,291	1,901	-3,180	3,140
Net financial items	-67	-286	122	-358	-991
Profit/loss after financial items	1,283	-1,577	2,023	-3,538	2,149
Taxes	-237	54	-307	10	4,297
Profit/loss after tax for the period	1,046	-1,523	1,716	-3,528	6,446
Items that may be reclassified subsequently to profit or loss					
Translation of foreign subsidiary	-13	-1,601	924	-1,510	-4,473
Comprehensive income for the period**	1,033	-3,123	2,640	-5,038	1,973

* The item Other operating income/expenses relates to exchange rate fluctuations.

**The entire profit is attributable to Parent Company shareholders

	April-June		Jan.-June		Full-year
	2021	2020	2021	2020	2021
Earnings per share (SEK)*	0.01	-0.02	0.02	-0.05	0.10
Number of shares					
Weighted average for the period	65,465,714	65,465,714	65,465,714	64,724,802	65,090,819
Number of shares at start of period	65,465,714	65,465,714	65,465,714	63,100,000	63,100,000
Number of shares at end of period	65,465,714	65,465,714	65,465,714	65,465,714	65,465,714
Share price at end of period, SEK	44.0	28.95	44.0	28.95	31.5

* Based on weighted average of the number of outstanding shares (basic and diluted)

Summary Balance Sheet

(SEK 000s)	June 30 2021	June 30 2020	Dec. 31 2020
Assets			
<i>Non-current assets</i>			
Intangible assets	16,236	18,321	15,832
Property, plant and equipment	11,340	10,181	12,497
Non-current financial assets	6,044	1,718	6,243
Current assets	31,317	21,987	27,958
Cash and cash equivalents	41,730	46,554	44,118
Total assets	106,667	98,841	106,648
Equity and liabilities			
Equity	89,805	80,151	87,165
Deferred tax	2,381	0	2,421
Non-current liabilities	1,285	6,357	3,318
Current liabilities	13,196	12,333	13,744
Total shareholders' equity and liabilities	106,667	100,669	106,648

Changes in equity

(SEK 000s)	June 30 2021	June 30 2020	Dec. 31 2020
Opening balance	87,165	35,620	35,620
Rights issue	0	49,572	49,571
Exchange rate difference	924	-1,513	-4,472
Profit/loss for the period	1,716	-3,528	6,446
Amount at end of period	89,805	80,151	87,165
Attributable to shareholders in Genovis AB	89,805	80,151	87,165

Key financial figures	June 30 2021	June 30 2020	Dec. 31 2020
Equity/assets ratio (%)	84	81	82
Equity per share at end of period* (SEK)	1.37	1.22	1.34

* Based on weighted average of the number of outstanding shares (basic and diluted).

Summary Statement of Cash Flows

(SEK 000s)	April-June		Jan.-June		Full-year
	2021	2020	2021	2020	2020
Profit/loss for the period	1,350	-1,291	1,901	-3,180	3,140
Adjustment for items not affecting cash flow	1,242	1,253	2,649	2,295	5,433
Changes in working capital	-4,172	205	-2,807	-383	-3,827
Net financial items	-167	-290	22	-361	-991
Cash flow from operating activities	- 1,747	-123	1,765	-1,629	3,755
Investing activities	-1,189	-15,758	-2,120	-16,499	-20,431
Cash flow after investing activities	-2,936	-15,881	-355	-18,128	-16,676
Financing activities	-1,263	902	-2,033	118	-3,770
Rights issue	0	-108	0	49,572	49,572
Cash flow for the period	-4,199	-15,087	-2,388	31,562	29,126
Cash and cash equivalents at start of period	45,929	61,641	44,118	14,992	14,992
Cash and cash equivalents at close of period	41,730	46,554	41,730	46,554	44,118

Financial information – Parent Company

Summary Income Statement

(SEK 000s)	April-June		Jan.- June		Full-year
	2021	2020	2021	2020	2020
Operating income incl. change in inventory, finished goods	13,523	9,577	23,209	19,189	61,860
Operating costs	-11,947	-9,192	-22,257	-20,909	-42,299
Operating profit/loss	1,576	385	952	-1,720	19,561
Net financial items	-	-215	210	-216	-686
Profit/loss for the period	1,576	170	1,162	-1,936	18,875

Summary Balance Sheet

(SEK 000s)	June 30 2021	June 30 2020	Dec. 31 2020
Assets			
Non-current assets	31,996	30,497	30,861
Current assets	41,289	21,617	41,953
Cash and cash equivalents	39,098	42,590	38,884
Total assets	112,383	94,704	111,698

(SEK 000s)	June 30 2021	June 30 2020	Dec. 31 2020
Equity and liabilities			
Restricted equity	16,366	16,366	16,366
Unrestricted equity	87,896	65,923	86,734
Liabilities			
Current liabilities	8,121	12,415	8,598
Total shareholders' equity and liabilities	112,383	94,704	111,698

Changes in equity

(SEK 000s)	June 30 2021	June 30 2020	Dec. 31 2020
Opening balance	103,100	34,654	34,654
Rights issue	0	49,571	49,571
Profit/loss for the period	1,162	-1,936	18,875
Equity at the end of the period	104,262	82,289	103,100
Attributable to shareholders in Genovis AB	104,262	82,289	103,100

Summary Statement of Cash Flows

(SEK 000s)	April-June		Jan.-June		Full-year
	2021	2020	2021	2020	2020
Profit/loss for the period	1,576	385	952	-1,720	19,561
Adjustment for items not affecting cash flow	408	312	767	608	1,279
Changes in working capital	-5,075	2,511	405	1,808	-23,030
Net financial items	-1	-216	210	-216	-1
Cash flow from operating activities	-3,092	2,992	2,334	480	-2,191
Investing activities	-1,189	-20,401	-2,120	-21,143	-22,178
Cash flow after investing activities	-4,281	-17,409	214	-20,663	-24,369
Financing activities	-	-108	-	49,572	49,572
Cash flow for the period	-4,281	-17,517	214	28,909	25,203
Cash and cash equivalents at start of period	43,379	60,107	38,884	13,681	13,681
Cash and cash equivalents at close of period	39,098	42,590	39,098	42,590	38,884

Auditor's review

This report has not been reviewed by the Company's auditor.

Statement by the Board of Directors and Chief Executive Officer

The Board of Directors and the Chief Executive Officer certify that this interim report provides a true and fair overview of the development of the Parent Company's and the Group's business activities, financial position and results of operations as well as the significant risks and uncertainties to which the Parent Company and the companies included in the Group are exposed.

Lund August 12, 2021
Genovis AB (publ.)

On behalf of the Board of Directors Fredrik Olsson
Chief Executive Officer

For more information

Additional information about the company is available on its website: genovis.com
For questions about this report, please contact: Fredrik Olsson, CEO, and President,
T: 0702-276 46 56.

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

This information is information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on August 12, 2021.